Pilar de la Rocha Mur

Sales & Marketing

Pilar de la Rocha Mur is Head of Clinical Operations EMEA (Europe, Middle East, and Africa) at BeiGene.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.